13,727 Neurocrine Biosciences, Inc. $NBIX Shares Bought by Impax Asset Management Group plc

Impax Asset Management Group plc lifted its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 8.6% in the 3rd quarter, Holdings Channel reports. The fund owned 173,727 shares of the company’s stock after buying an additional 13,727 shares during the period. Impax Asset Management Group plc’s holdings in Neurocrine Biosciences were worth $24,641,000 as of its most recent filing with the SEC.

Other large investors also recently made changes to their positions in the company. Entrust Financial LLC raised its stake in shares of Neurocrine Biosciences by 62.9% during the third quarter. Entrust Financial LLC now owns 202 shares of the company’s stock valued at $29,000 after purchasing an additional 78 shares in the last quarter. Raleigh Capital Management Inc. raised its holdings in shares of Neurocrine Biosciences by 561.8% in the 3rd quarter. Raleigh Capital Management Inc. now owns 225 shares of the company’s stock worth $32,000 after purchasing an additional 191 shares in the last quarter. Basecamp Wealth Advisors LLC lifted its stake in Neurocrine Biosciences by 582.9% during the first quarter. Basecamp Wealth Advisors LLC now owns 239 shares of the company’s stock valued at $31,000 after purchasing an additional 204 shares during the last quarter. Cassaday & Co Wealth Management LLC acquired a new stake in Neurocrine Biosciences during the first quarter valued at approximately $33,000. Finally, TrinityBridge Ltd acquired a new stake in Neurocrine Biosciences during the second quarter valued at approximately $45,000. Institutional investors and hedge funds own 92.59% of the company’s stock.

Insider Transactions at Neurocrine Biosciences

In related news, CFO Matt Abernethy sold 2,311 shares of Neurocrine Biosciences stock in a transaction on Monday, September 14th. The stock was sold at an average price of $157.20, for a total transaction of $363,289.20. Following the completion of the sale, the chief financial officer owned 42,808 shares of the company’s stock, valued at approximately $6,729,417.60. This trade represents a 5.12% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director George Morrow sold 7,500 shares of the business’s stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $145.79, for a total value of $1,093,425.00. Following the completion of the transaction, the director owned 10,386 shares in the company, valued at $1,514,174.94. This trade represents a 41.93% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 18,137 shares of company stock valued at $2,829,332. 4.60% of the stock is owned by insiders.

Neurocrine Biosciences Stock Up 0.4%

NBIX stock opened at $165.92 on Wednesday. Neurocrine Biosciences, Inc. has a 12-month low of $122.14 and a 12-month high of $186.12. The company has a market cap of $16.79 billion, a price-to-earnings ratio of 24.62, a PEG ratio of 0.67 and a beta of 0.36. The company has a 50 day moving average of $148.99 and a two-hundred day moving average of $149.20.

Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) last issued its earnings results on Monday, November 2nd. The company reported $3.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.91 by $1.38. Neurocrine Biosciences had a net margin of 18.98% and a return on equity of 23.39%. The company had revenue of $1.12 billion during the quarter, compared to analyst estimates of $1.04 billion. During the same quarter last year, the business posted $2.04 EPS. The company’s revenue for the quarter was up 41.3% on a year-over-year basis. On average, research analysts anticipate that Neurocrine Biosciences, Inc. will post 8.41 EPS for the current year.

Analysts Set New Price Targets

A number of analysts recently weighed in on NBIX shares. Stifel Nicolaus raised their target price on shares of Neurocrine Biosciences from $188.00 to $215.00 and gave the stock a “buy” rating in a report on Friday, July 31st. Citigroup upped their price target on Neurocrine Biosciences from $249.00 to $253.00 and gave the company a “buy” rating in a report on Thursday, September 3rd. Morgan Stanley increased their price objective on Neurocrine Biosciences from $185.00 to $191.00 and gave the company an “equal weight” rating in a research report on Friday, November 13th. Guggenheim increased their price objective on Neurocrine Biosciences from $207.00 to $224.00 and gave the company a “buy” rating in a research report on Wednesday, November 4th. Finally, Mizuho raised Neurocrine Biosciences to a “hold” rating in a research note on Wednesday, September 16th. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Neurocrine Biosciences has an average rating of “Moderate Buy” and a consensus target price of $202.59.

View Our Latest Research Report on Neurocrine Biosciences

Neurocrine Biosciences Company Profile

(Free Report)

Neurocrine Biosciences is a biopharmaceutical company focused on developing and commercializing treatments for neurological, endocrine and related disorders. Founded in 1992 and headquartered in San Diego, California, the company conducts research and development alongside its commercial operations. Its marketed medicines include INGREZZA (valbenazine), approved in the United States for tardive dyskinesia and chorea associated with Huntington disease, and CRENESSITY (crinecerfont), used with glucocorticoid replacement therapy to treat classic congenital adrenal hyperplasia in adults and children.

Recommended Stories

Want to see what other hedge funds are holding NBIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report).

Institutional Ownership by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.